Efficacy and Safety of Ixabepilone (BMS-247550) in a Phase II Study of Patients With Advanced Breast Cancer Resistant to an Anthracycline, a Taxane, and Capecitabine
Edith A. Perez(Unknown), Gabriel N. Hortobágyi(The University of Texas MD Anderson Cancer Center), Can Cai(Cornell University), Xavier Pivot(Levi Strauss (United States)), Linda T. Vahdat(Dartmouth–Hitchcock Medical Center), Linda D. Bosserman(City of Hope), Eva Thomas(Cornell University), Brian P. Mullaney(Cornell University), Guillermo Lerzo, Ronald Peck(Cornell University), Patrice Viens(Centre National de la Recherche Scientifique)
Cited by 392
Related Papers
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
|Cancer Cell|2004|1.9k
Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance
|Nature|2015|1.8k
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
|Journal of Clinical Oncology|2017|1.7k
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2018|1.3k
Connecting copper and cancer: from transition metal signalling to metalloplasia
|Nature reviews. Cancer|2021|1.3k